The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy

The administration of antibodies blocking the immune checkpoint molecules programmed cell death protein 1 (PD-1) or programmed cell death 1 ligand 1 (PD-L1) has evolved as a very promising treatment option for cancer patients. PD-1/PD-L1 inhibition has significantly enhanced expansion, cytokine secr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tunger, Antje, Sommer, Ulrich, Wehner, Rebekka, Kubasch, Anne Sophie, Grimm, Marc-Oliver, Bachmann, Michael Philipp, Platzbecker, Uwe, Bornhäuser, Martin, Baretton, Gustavo, Schmitz, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832659/
https://www.ncbi.nlm.nih.gov/pubmed/31557787
http://dx.doi.org/10.3390/jcm8101534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832659/
https://www.ncbi.nlm.nih.gov/pubmed/31557787
http://dx.doi.org/10.3390/jcm8101534

Ejemplares similares